Bart Neyns, MD, PhD, Universitair Ziekenhuis Brussel, Brussels, Belgium, discusses findings from a Phase I trial (NCT03233152) of intracranial administration of nivolumab, ipilimumab, and autologous myeloid dendritic cells (myDC) in patients with recurrent high-grade glioma (rHGG) following tumor resection. The study found that this approach is safe and well-tolerated, warranting further studies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
